Investors & Media

Events & Presentations

  • Type:
  • Year:
  • Dec. 9 - 12, 2017   //  Atlanta, GA

    Kamada to participate in 59th ASH Annual Meeting & Exposition

    The meeting will provide an invaluable educational experience and the opportunity to review thousands of scientific abstracts highlighting updates in the hottest topics in hematology. Network with top minds in the field and a global community of more than 25,000 hematology professionals from every subspecialty.
  • Nov. 15 - 16, 2017   //  London, UK

    Kamada to participate in Jefferies 2017 London Healthcare Conference

    This year, we hosted 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.
  • Nov. 6 - 8, 2017   //  Berlin, Germany

    Kamada to participate in 23rd Annual InternationalPartnering Conference Bio-Europe

    BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.

  • Oct. 22 - 27, 2017   //  Calgary, Alberta, Canada

    Kamada to participate and present at the RITA (Rabies in the Americas) 2017 meeting

    The meeting provides an opportunity for researchers, health professionals, international, national and local managers of rabies programs, wildlife biologists, laboratory personnel and other people interested in advancing knowledge of rabies surveillance, prevention and control, to meet each other, to share their successes and also to discuss the challenges to be met.

  • Sep. 26, 2017   //  New-York City, USA

    Kamada to participate in Ladenburg Thalmann’s 3rd annual Healthcare Conference

    The Ladenburg 2017 Healthcare Conference will feature presentations from CEOs of an extensive range of public and private life sciences companies across the biopharmaceutical and medical technology sectors and will include one-on-one meetings with investors.
  • Sep. 25 - 27, 2017   //  New-York City, USA

    Kamada to participate in Cantor Fitzgerald’s 3rd Annual Healthcare Conference 2017

    The conference is a three day multi-track event, which will feature over 200 innovative industry leaders from public and private companies for an in-depth discussion of the developments and trends shaping biotechnology, specialty pharmaceuticals, medical technology, healthcare facilities and services, and life sciences tools and diagnostics.
  • Sep. 9 - 13, 2017   //  Milan, Italy

    Kamada to participate in ERS International Congress 2017

    This association organise a range of scientific and educational events including the ERS International Congress, the largest conference in the respiratory field. Other events include courses, research seminars, the Lung Science Conference and, Sleep and Breathing conference.
  • Sep. 5 - 6, 2017   //  Shanghai, China

    Kamada to participate in 6th Annual Bioplasma Asia 2017

    Over the past 5 years, Bioplasma World Asia has established itself as Asia's definitive meeting place for plasma fractionators, investors, regulators and technology providers. With the mission to propel Asia towards self-sufficiency, it has brought together over 400 opinion leaders from Asia and globally from 2012 to 2015, and helped hundreds of plasma and blood products industry players to address pressing issues, share best practices and form partnerships.
  • Aug. 30 - 31, 2017   //  Wolfsberg, Switzerland

    Kamada to participate in the meeting of the Partners for Rabies Prevention (PRP)

    Annual meeting of the informal group Partners for Rabies Prevention (PRP). The PRP is an group of key representatives for rabies within the World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), rabies vaccine manufacturing companies, academics, implementers, and Non-Governmental Organizations sat together informally, with each having a voice in discussions on how to tackle the neglect of rabies with practical ways forward.
  • Aug. 1, 2017   //  Conference Call

    Kamada to Host Second Quarter 2017 Financial Results Conference Call on August 1

    Direct webcast link: http://public.viavid.com/index.php?id=125164 Rehovot, Israel – July 27, 2017 -- Kamada Ltd. (NASDAQ and TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will release financial results for the second quarter ended June 30, 2017 prior to the open of the U.S. financial markets on Tuesday, August 1. Kamada management will host an investment community conference call on Tuesday, August 1 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 888-221-9591 (from within the U.S.), 1 80 924 6042 (from Israel), or 719-325-4893 (International) and entering the conference identification number: 2753969. The call will also be webcast live on the Internet on the Company's website at www.kamada.com. A replay of the call will be accessible two hours after its completion through August 15 by dialing 844-512-2921 (from within the U.S.) or 412-317-6671 (from outside the U.S.) and entering the conference identification number: 2753969. The call will also be archived for 90 days on the Company's website at www.kamada.com. About Kamada Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. AAT is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. The Company's flagship product is Glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets Glassia® in the U.S. through a strategic partnership with Baxalta (formerly Baxter International Inc.'s BioScience business and now part of Shire plc) and in other counties through local distributors. In addition to Glassia®, Kamada has a product line of seven other pharmaceutical products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, India and other countries in Latin America and Asia. Kamada has five late-stage plasma-derived protein products in development, including an inhaled formulation of AAT for the treatment of AAT deficiency that completed a pivotal Phase 2/3 clinical trial in Europe. Kamada has also completed its Phase 2 clinical trial in the U.S. for the treatment of AAT deficiency using our proprietary inhaled AAT. In addition, Kamada's intravenous AAT is in development for other indications such as type-1 diabetes, GvHD and prevention of lung transplant rejection. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 10 pharmaceutical products in Israel that are manufactured by third parties. Cautionary Note Regarding Forward-Looking Statements This release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecast, commercial results, timing and results of clinical trials and EMA and U.S. FDA authorizations. Forward-looking statements are based on Kamada's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in the U.S. FDA or the EMA approval process, additional competition in the AATD market or other markets in which Kamada operates or intends to operate, or further regulatory delays. The forward-looking statements made herein speak only as of the date of this announcement and Kamada undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. CONTACTS: Gil Efron Deputy CEO & Chief Financial Officer IR@kamada.com Bob Yedid LifeSci Advisors, LLC 646-597-6989 Bob@LifeSciAdvisors.com